These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
572 related articles for article (PubMed ID: 15899391)
21. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy. Chien JH; Tang JL; Chen RL; Li CC; Lee CP Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297 [TBL] [Abstract][Full Text] [Related]
22. Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. Cilloni D; Messa F; Gottardi E; Fava M; Arruga F; Defilippi I; Carturan S; Messa E; Morotti A; Giugliano E; Rege-Cambrin G; Alberti D; Baccarani M; Saglio G Cancer; 2004 Sep; 101(5):979-88. PubMed ID: 15329907 [TBL] [Abstract][Full Text] [Related]
23. Chronic myeloid leukemia with a novel four-way t(6;13;9;22)(p21;q32;q34;q11.2) successfully treated with imatinib mesylate. Kubota Y; Waki M Cancer Genet Cytogenet; 2010 Sep; 201(2):135-6. PubMed ID: 20682400 [No Abstract] [Full Text] [Related]
24. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib. Morel F; Bris MJ; Herry A; Calvez GL; Marion V; Abgrall JF; Berthou C; Braekeleer MD Eur J Haematol; 2003 Apr; 70(4):235-9. PubMed ID: 12656747 [TBL] [Abstract][Full Text] [Related]
25. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management. Martinelli G; Iacobucci I; Soverini S; Cilloni D; Saglio G; Pane F; Baccarani M Hematol Oncol; 2006 Dec; 24(4):196-204. PubMed ID: 16988930 [TBL] [Abstract][Full Text] [Related]
26. Clonal evolution with inv(11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia. Yamamoto M; Kakihana K; Kurosu T; Murakami N; Miura O Cancer Genet Cytogenet; 2005 Mar; 157(2):104-8. PubMed ID: 15721630 [TBL] [Abstract][Full Text] [Related]
27. Simultaneous occurrence of t(9;22)(q34;q11.2) and t(16;16)(p13;q22) in a patient with chronic myeloid leukemia in blastic phase. Zámecníkova A; Al Bahar S; Ramesh P Cancer Genet Cytogenet; 2008 Jun; 183(2):109-13. PubMed ID: 18503829 [TBL] [Abstract][Full Text] [Related]
28. Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib. Agirre X; Román-Gómez J; Vázquez I; Jiménez-Velasco A; Larráyoz MJ; Lahortiga I; Andreu EJ; Márquez J; Beltrán de Heredia JM; Odero MD; Prósper F; Calasanz MJ Cancer Genet Cytogenet; 2005 Jul; 160(1):22-6. PubMed ID: 15949566 [TBL] [Abstract][Full Text] [Related]
29. Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ Chronic Myeloid Leukemia patients treated with imatinib mesylate. Fugazza G; Miglino M; Bruzzone R; Quintino S; Gatti AM; Grasso R; Gobbi M; Frassoni F; Sessarego M J Exp Clin Cancer Res; 2004 Jun; 23(2):295-9. PubMed ID: 15354415 [TBL] [Abstract][Full Text] [Related]
30. Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model. Park J; Kim KI; Koh Y; Won NH; Oh JM; Lee DS; Kim BK; Ahn KS; Yoon SS Exp Hematol; 2010 Sep; 38(9):773-81. PubMed ID: 20438801 [TBL] [Abstract][Full Text] [Related]
31. E355G mutation appearing in a patient with e19a2 chronic myeloid leukaemia resistant to imatinib. Bennour A; Beaufils N; Sennana H; Meddeb B; Saad A; Gabert J J Clin Pathol; 2010 Aug; 63(8):737-40. PubMed ID: 20702476 [TBL] [Abstract][Full Text] [Related]
32. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction]. Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019 [TBL] [Abstract][Full Text] [Related]
33. Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy. Atallah E; Talpaz M; O'brien S; Rios MB; Guo JQ; Arlinghaus R; Fernandes-Reese S; Kantarjian H Cancer; 2002 Jun; 94(11):2996-9. PubMed ID: 12115389 [TBL] [Abstract][Full Text] [Related]
34. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063 [TBL] [Abstract][Full Text] [Related]
35. Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant. Qin YZ; Jiang B; Jiang Q; Zhang Y; Jiang H; Li JL; Zhu HH; Li LD; Liu YR; Chen SS; Huang XJ Acta Haematol; 2008; 120(3):146-9. PubMed ID: 19039205 [TBL] [Abstract][Full Text] [Related]